Earn credits and unlock exclusive offers with iXCells Loyalty Program!

In Vitro Liver Fibrosis Assays

Join our dynamic and fast growing company, and be a part of our vision to revolutionize drug discovery. We are dedicated to providing innovative solutions in the field, with a particular emphasis on disease-relevant cellular models.

In Vitro Liver Fibrosis Assays

Liver fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins including collagen that occurs in most types of chronic liver diseases. The main causes of liver fibrosis include chronic HCV infection, alcohol abuse, and nonalcoholic steatohepatitis (NASH). Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. 

We provide in vitro liver fibrosis assays using human primary hepatic stellate cells (normal or NASH adult donors) to meet your needs in discovery of antifibrotic drugs, or investigating mechanistic tox pathway, and predicting fibrogenic effect.

  • Primary Adult Human Hepatic Stellate Cells (Normal & NASH)
  • TGFb-dependent fibrogenic gene induction (qRT-PCR, IF)
  • High throughput screen available

Figure 1

Figure 1. Human Hepatic Stellate Cells from a NASH patient and a healthy donor were cultured for 2 days post thaw, and harvested for qRT-PCR analysis. The fibrogenic genes are upregulated in NASH cells compared to normal cells. n=3. Error Bar: StdEV.

Figure 2

Figure 2. Human Hepatic Stellate Cells from the healthy donor were seeded on 6-well plates for transcriptomic analysis (A) or on 8-well chamber slides for immunofluorescence staining analysis (B). Prior to TGFb stimulation, cells were incubated with ALK5 Inhibitor (LY2157299) for 30 minutes followed by stimulation for 24h with 2.5 ng/ml TGFb.

Figure 3

Figure 3. Human Hepatic Stellate Cells from the NASH patient were seeded on 6-well plates for transcriptomic analysis (A) or 8-well chamber slides for immunofluorescence staining analysis (B). Cells were treated with or without ALK5 inhibitor (LY2157299), and harvested 24hr post treatment.